Catalyst Pharmaceuticals to Exit S&P SmallCap 600 on July 15 After Angelini Deal
CPRX•Catalyst Pharmaceuticals will be deleted from the S&P SmallCap 600 before market open on July 15, 2026, when Solaris Energy Infrastructure takes its place. The removal follows Angelini Pharma’s pending acquisition of Catalyst, which is expected to close soon subject to final conditions.
1. Index Removal from S&P SmallCap 600
Catalyst Pharmaceuticals will be removed from the S&P SmallCap 600 effective July 15, 2026, ahead of trading. Solaris Energy Infrastructure will take its slot, shifting the index’s sector weight from Health Care to Energy.
2. Acquisition Trigger
The removal follows Angelini Pharma S.p.A.’s pending acquisition of Catalyst Pharmaceuticals, expected to close soon subject to final closing conditions. Completion of the deal will render CPRX ineligible for continued index membership.
3. Potential Market Impact
Passive funds tracking the S&P SmallCap 600 must sell CPRX shares at removal, which could increase trading volume and exert downward pressure on the stock. Investors may adjust positions in anticipation of the acquisition’s closing.
